Navigation Links
Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis

SOUTH SAN FRANCISCO, July 9 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc., announced today it has initiated a Phase II proof-of-concept study of Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, a chronic and potentially sight-threatening inflammation of the eye. The randomized, double-masked, placebo-controlled study will evaluate the safety and efficacy of Simulect as maintenance therapy in 56 patients. During the study, patients will undergo tapering of concomitant immunosuppressive medications, the mainstay of treatments for noninfectious uveitis. This is the second mid-stage trial for basiliximab run by Cerimon, which began a Phase IIb study for patients with moderate-to-severe, steroid-refractory ulcerative colitis (UC) in April 2007.

"The initiation of this proof-of-concept study is part of our overall strategy to seek additional indications for already marketed drugs in areas with significant unmet medical needs," stated Paul Sekhri, President and CEO of Cerimon Pharmaceuticals. "In noninfectious uveitis, we believe Simulect has the potential to significantly improve the quality of life for patients by reducing adverse events often associated with oral or topical corticosteroids while maintaining effective control of their inflammation."

Basiliximab is a monoclonal antibody that selectively blocks the interleukin-2 (IL-2) receptor. This mechanism of action provides highly targeted inhibition of the T-lymphocyte activation that is involved in serious immune-related diseases including noninfectious uveitis. In February 2006, the Company licensed basiliximab from Novartis Pharma AG for the treatment of Inflammatory Bowel Disease (IBD) and initiated a Phase IIb clinical study for the treatment of moderate-to-severe, steroid-refractory ulcerative colitis the following year. In December 2007, Cerimon entered into an agreement with Novartis to conduct a proof-of-concept study for basiliximab for the treatment of noninfectious uveitis.

About Noninfectious Uveitis

Uveitis is an inflammation of the internal structures of the eye. Uveitis can be described by the underlying condition that causes it: autoimmune (noninfectious), bacterial, viral, parasitic and eye trauma, and by the part of the eye that it affects: anterior, intermediate, posterior and panuveitis. Noninfectious uveitis affects approximately two hundred forty thousand people worldwide and can lead to complications, such as glaucoma, cataract and total vision loss. Current treatments include topical and oral corticosteroids, steroidal implants and immunosuppressive drugs; however, these generally have limited success and can lead to adverse events.

About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for autoimmune diseases, inflammation and pain. Cerimon believes these new treatment options will enable physicians to further improve the lives of their patients.

Cerimon currently has two drugs in clinical development. The Company's autoimmune program has two development programs. The lead program is a Phase IIb study in which Simulect(R) (basiliximab) is being assessed as a treatment for moderate-to-severe, steroid-refractory ulcerative colitis (UC). The second program is studying Simulect as a treatment for noninfectious uveitis in a Phase II study. Cerimon's lead asset in its pain portfolio is the Company's topical formulations of diclofenac. The Company is in mid-stage clinical testing with its topical diclofenac products.

The Company continues to seek additional assets to add to its development pipeline and is financed by the premier investors MPM, Nomura Phase4 Ventures and OrbiMed Advisors.

For more information on Cerimon, please visit the Company's website at .

SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
2. Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
3. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
4. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
7. Isis Pharmaceuticals Conference Call Notice
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Post Your Comments:
(Date:11/24/2015)... 24, 2015 . ... adds Latest Guidebook for Chinese Medical Device ... published in November 2015 to the medical devices ... library at . ... growing global economies with a fifth population in ...
(Date:11/24/2015)... , Nov. 24, 2015  Figure 1, a ... and share medical cases, has launched a new completely ... the web version allows radiologists, who work primarily on ... To further engage with its radiologist user base, Figure ... of North America (RSNA) Annual ...
(Date:11/24/2015)... 24, 2015 --> ... MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists ... grow at the fastest rates? This visiongain ... trends, opportunities and prospects there. ,  ,Our 199-page report ... lucrative areas in the industry and the future market ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... Cancer patients, survivors, caregivers, family ... a live taping of the next CURE Connections® video series on ... 2015 Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , ...
(Date:11/24/2015)... ... ... American Family Care (AFC), the nation’s leading provider of urgent care and accessible ... Atlanta’s North Point Mall. The clinic is designed to test the concept of addressing ... operate through Dec. 24. , Holiday Pop-Up Clinic , Official Opening November 27, 6 ...
(Date:11/24/2015)... , ... November 24, 2015 , ... With Thanksgiving right ... is sharing safety tips to help protect your family and vehicle. , According to ... the 2013 Thanksgiving holiday weekend. Amica is sharing the following safety tips from the ...
(Date:11/24/2015)... Irvine, CA (PRWEB) , ... November 24, 2015 , ... Cold Shoulder , LLC ... Kickstarter last week and hit their goal of $20,000 in under 10 hours. ... aims to bring the new PRO Weight Loss Vest to the market. , The ...
(Date:11/24/2015)... PALMYRA, Wis (PRWEB) , ... November 24, 2015 ... ... Process scholarship award at Cleveland University-Kansas City (CU-KC), in Overland Park, ... scholarship from Chiropractor and University President Carl S. Cleveland III on October 16. ...
Breaking Medicine News(10 mins):